Abstract
Mortality in patients admitted to hospital with severe sepsis and septic shock is still unacceptably high, despite advances in understanding of the pathophysiological mechanisms and the implementation of evidence-based guidelines. Severe sepsis is often associated with the decrease in immunoglobulin plasma levels (Ig) and the presence of hypogammaglobulinaemia is related to bad outcome. Ig plays a pivotal role in immune and inflammatory response and therapy with intravenous Ig is currently recommended in several no septic diseases. Diverse meta-analysis showed that the adjunctive therapy with intravenous polyclonal Ig, particularly with preparation enriched in IgM component, may be beneficial also in patients with severe sepsis and septic shock.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- SSC =:
-
Surviving Sepsis Campaign
- ICU =:
-
Intensive Care Unit
- SIRS =:
-
Systemic Inflammatory Response Syndrome
- IgG/IgM =:
-
Immunoglobulin G/M
- IgGAM =:
-
Immunoglobulin IgM enriched
- SSP =:
-
Sepsis Stewardship Program
- SOFA =:
-
Sequential Organ Failure Assessment
- SAPS =:
-
Simplified Acute Physiology Score
- RCT =:
-
Randomized Controlled Trial
- CVP =:
-
Central Venous Pressure
- SvcO2 =:
-
Central Venous Oxygen Saturation
- ALI =:
-
Acute Lung Injury
- ARDS =:
-
Acute Respiratory Distress Syndrome
- rhAPC =:
-
recombinant human Activated C Protein
References
Malacarne P, Langer M, Nascimben E et al (2008) Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Crit Care Med 36(4):1105–1113
Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296–327
Dellinger RP, Levy MM, Rhodes A et al (2012) (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 39(2):165–228
Barochia AV, Cui X, Vitberg D et al (2010) Bundled care for septic shock: an analysis of clinical trials. Crit Care Med 38(2):668–678
Reinhart K, Brunkhorst FM, Bone H-G et al. (2010) Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2 k guidelines of the german sepsis society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the german interdisciplinary association of intensive care and emergency medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger. Med. Sci. Gms E-J.8:Doc14
Taccone FS, Stordeur P, De Backer D (2009) Gamma-globulin levels in patients with community-acquired septic shock. Shock Augusta Ga. 32(4):379–385
Venet F, Gebeile R, Bancel J et al (2011) Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol 11(12):2086–2090
Walpen AJ, Laumonier T, Aebi C (2004) Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. Xenotransplantation 11(2):141–148
Norrby-Teglund A, Haque KN, Hammarström L (2006) Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 260(6):509–516
Trautmann M, Held TK, Susa M et al (1998) Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 111(1):81–90
Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10(11):778–786
Wenisch C, Parschalk B, Patruta S (1999) Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with gram-negative septicemia. Infection 27(3):183–186
Autenrieth IB, Schwarzkopf A, Ewald JH (1995) Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations. Antimicrob Agents Chemother 39(9):1965–1969
Schedel I, Dreikhausen U, Nentwig B et al (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 19(9):1104–1113
Tugrul S, Ozcan PE, Akinci O et al (2002) The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit. Care Lond. Engl. 6(4):357–362
Karatzas S, Boutzouka E, Venetsanou K (2002) The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Crit. Care Lond. Engl. 6(6):543–544; author reply 545
RodrÃguez A, Rello J, Neira J et al (2005) Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock Augusta Ga. 23(4):298–304
Hentrich M, Fehnle K, Ostermann H et al (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34(5):1319–1325
Turgeon AF, Hutton B, Fergusson DA et al (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146(3):193–203
Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35:2677–2685
Laupland KB, Kirkpatrick AW, Delaney A (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 35(12):2686–2692
Alejandria MM, Lansang MA, Dans LF, Mantaring JB. (2001) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst. Rev. Online. (2):CD001090
Werdan K, Pilz G, Bujdoso O et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35(12):2693–2701
Cavazzuti I, Rinaldi L, Donno L (2010) Early use of immunoglobulin in septic shock. Critical Care; 14 S1: S10 (30th International Symposium on Intensive Care and Emergency Medicine,9-12 Marzo 2010, Brussels, Belgio)
Cavazzuti I, Rinaldi L, Braccini S et al (2009). Effects of intravenous IgM-enriched immunoglobulins on muscle tissue microcirculation in septic shock: a preliminary report. Intensive Care Med. Intensive Care Med; 35 S1: S239
Molnà r Z, Nierhause A, Esen F (2013) Immunoglobulin in Sepsis: Which Patients will Benefit the Most?. Annual Update on Intensive Care and Medicine Editor JL Vincent, Springer-Verlag, Berlin, In, pp 145–152
Berlot G, Vassallo MC, Busetto N et al (2012) Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis. J Crit Care 27:167–171
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this paper
Cite this paper
Girardis, M., Serafini, G., Cavazzuti, I. (2014). Immunoglobulin as Adjunctive Therapy in Sepsis. In: Gullo, A. (eds) Anaesthesia, Pharmacology, Intensive Care and Emergency A.P.I.C.E.. Springer, Milano. https://doi.org/10.1007/978-88-470-5516-2_15
Download citation
DOI: https://doi.org/10.1007/978-88-470-5516-2_15
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5515-5
Online ISBN: 978-88-470-5516-2
eBook Packages: MedicineMedicine (R0)